Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | NGS: a valuable tool for elucidating the genetic landscape of AML

Torsten Haferlach • 10 Apr 2019
EBMT 2019
Acute Myeloid Leukemia Leukemia

Torsten Haferlach, MD, of Munich Leukemia Laboratory, Munich, Germany, discusses how next-generation sequencing (NGS) can significantly facilitate the uncovering of genetic mutations associated with acute myeloid leukemia (AML). Speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany, Prof. Haferlach reports that NGS can enable scientists to gain important information for diagnosis, prognostication and measurable residual disease (MRD) in the context of AML.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Torsten Haferlach

The value of WGS and whole transcriptome sequencing in the diagnosis of hematological malignancies
3:33
The value of WGS and whole transcriptome sequencing in the diagnosis of hematological malignancies
Torsten Haferlach • 9 Dec 2023
Implementing AI in hematology and the challenges this will overcome
1:52
Implementing AI in hematology and the challenges this will overcome
Torsten Haferlach • 9 Dec 2023
Why do we need AI in the hematology clinic?
2:57
Why do we need AI in the hematology clinic?
Torsten Haferlach • 9 Dec 2023
Role of NGS in acute leukemias
1:53
Role of NGS in acute leukemias
Torsten Haferlach • 17 Sep 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals